DXCM
DexCom Inc.
$60.61
-0.49%
2026-05-08
About DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Key Fundamentals
P/E Ratio
26.03
Forward P/E
19.86
EPS (TTM)
$2.33
ROE
35.6%
Revenue Growth (YoY)
15.0%
Profit Margin
19.3%
Debt/Equity
46.83
Price/Book
7.92
Beta
1.40
Market Cap
$23.40B
Avg Volume (10D)
5.7M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$74.49
60D Low
$56.72
Avg Volume
4.2M
Latest Close
$60.61
Get breakout alerts for DXCM
Sign up for Breakout Scanner to receive daily notifications when DXCM triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
DexCom Inc. (DXCM) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors DXCM daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. DXCM operates in the Healthcare sector within the Medical Devices industry. Data is provided for informational purposes only and does not constitute financial advice.